Celebrex Should Stay Despite Risk - Panel (Reuters)


Reuters - Pfizer Inc.'s
arthritis medicine Celebrex should stay on the market even
though studies show it can raise the risk of heart problems, a
U.S. advisory panel said on Friday.

Read more...